Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease

Brain Research

Volumn 1362, Issue , 2010, Pages 13-22

  Thorsell, Annika ^a   Bjerke, Maria ^a   Gobom, Johan ^a   Brunhage, Eva ^a   Vanmechelen, Eugeen ^b   Andreasen, Niels ^c   Hansson, Oskar ^d   Minthon, Lennart ^d   Zetterberg, Henrik ^a   Blennow, Kaj ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b INNOGENETICS   (Belgium)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

AD; Alzheimer's disease; cerebrospinal fluid; CSF; Immunoprecipitation; IP; mass spectrometry; MCI; mild cognitive impairment; MS

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; NEUROGRANIN; TAU PROTEIN; TAURINE TRANSPORTER;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; PRIORITY JOURNAL; SYNAPSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE DEGENERATION; NEUROGRANIN; SYNAPSES;

EID: 78149362552     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.09.073     Document Type: Article

References (32)

1. A. Alonso, T. Zaidi, M. Novak, I. Grundke-Iqbal, and K. Iqbal Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments Proc. Natl Acad. Sci. USA 98 2001 6923 6928
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1987 Arlington, VA, USA
3. K. Blennow, and H. Hampel CSF markers for incipient Alzheimer's disease Lancet Neurol. 2 2003 605 613
4. P. Davidsson, and K. Blennow Neurochemical dissection of synaptic pathology in Alzheimer's disease Int. Psychogeriatr. 10 1998 11 23
5. S.T. DeKosky, and S.W. Scheff Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity Ann. Neurol. 27 1990 457 464
6. S.T. DeKosky, S.W. Scheff, and S.D. Styren Structural correlates of cognition in dementia: quantification and assessment of synapse change Neurodegeneration 5 1996 417 421
7. D. Gerendasy Homeostatic tuning of Ca2+ signal transduction by members of the calpacitin protein family J. Neurosci. Res. 58 1999 107 119
8. D.D. Gerendasy, and J.G. Sutcliffe RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes Mol. Neurobiol. 15 1997 131 163
9. O. Heinonen, H. Soininen, H. Sorvari, O. Kosunen, L. Paljarvi, E. Koivisto, and P.J. Riekkinen Sr. Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's disease Neuroscience 64 1995 375 384
10. W.G. Honer Pathology of presynaptic proteins in Alzheimer's disease: more than simple loss of terminals Neurobiol. Aging 24 2003 1047 1062
11. K.P. Huang, F.L. Huang, T. Jager, J. Li, K.G. Reymann, and D. Balschun Neurogranin/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling J. Neurosci. 24 2004 10660 10669
12. Y. Ishihama, J. Rappsilber, J.S. Andersen, and M. Mann Microcolumns with self-assembled particle frits for proteomics J. Chromatogr. A 979 2002 233 239
13. E. Klann, S.J. Chen, and J.D. Sweatt Increased phosphorylation of a 17-kDa protein kinase C substrate (P17) in long-term potentiation J. Neurochem. 58 1992 1576 1579
14. L. Li, Y. Li, X. Ji, B. Zhang, H. Wei, and Y. Luo The effects of retinoic acid on the expression of neurogranin after experimental cerebral ischemia Brain Res. 1226 2008 234 240
15. E. Masliah, M. Mallory, M. Alford, R. DeTeresa, L.A. Hansen, D.W. McKeel Jr., and J.C. Morris Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease Neurology 56 2001 127 129
16. E. Masliah, M. Mallory, L. Hansen, R. DeTeresa, M. Alford, and R. Terry Synaptic and neuritic alterations during the progression of Alzheimer's disease Neurosci. Lett. 174 1994 67 72
17. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, M. Jonsson, S.K. Herukka, W.M. van der Flier, M.A. Blankenstein, M. Ewers, K. Rich, E. Kaiser, M. Verbeek, M. Tsolaki, E. Mulugeta, E. Rosen, D. Aarsland, P.J. Visser, J. Schroder, J. Marcusson, M. de Leon, H. Hampel, P. Scheltens, T. Pirttila, A. Wallin, M.E. Jonhagen, L. Minthon, B. Winblad, and K. Blennow CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment Jama 302 2009 385 393
18. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
19. A.B. Oestreicher, J.J. Hens, A. Marquart, M. Mercken, P.N. De Graan, H. Zwiers, and W.H. Gipsen Monoclonal antibody NM2 recognizes the protein kinase C phosphorylation site in B-50 (GAP-43) and in neurogranin (BICKS) J. Neurochem. 62 1994 881 889
20. M. Otto, J. Wiltfang, H. Tumani, I. Zerr, M. Lantsch, J. Kornhuber, T. Weber, H.A. Kretzschmar, and S. Poser Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease Neurosci. Lett. 225 1997 210 212
21. J.H. Pak, F.L. Huang, J. Li, D. Balschun, K.G. Reymann, C. Chiang, H. Westphal, and K.P. Huang Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice Proc. Natl Acad. Sci. USA 97 2000 11232 11237
22. R.C. Petersen Mild cognitive impairment as a diagnostic entity J. Intern. Med. 256 2004 183 194
23. E. Portelius, S.F. Hansson, A.J. Tran, H. Zetterberg, P. Grognet, E. Vanmechelen, K. Hoglund, G. Brinkmalm, A. Westman-Brinkmalm, E. Nordhoff, K. Blennow, and J. Gobom Characterization of tau in cerebrospinal fluid using mass spectrometry J. Proteome Res. 7 2008 2114 2120
24. P.H. Reddy, G. Mani, B.S. Park, J. Jacques, G. Murdoch, W. Whetsell Jr., J. Kaye, and M. Manczak Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction J. Alzheimers Dis. 7 2005 103 117 discussion 173-80
25. A.E. Roher, J.D. Lowenson, S. Clarke, A.S. Woods, R.J. Cotter, E. Gowing, and M.J. Ball beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease Proc. Natl Acad. Sci. USA 90 1993 10836 10840
26. J.B. Standridge Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease Curr. Alzheimer Res. 3 2006 95 108
27. G.B. Stokin, and L.S. Goldstein Axonal transport and Alzheimer's disease Annu. Rev. Biochem. 75 2006 607 627
28. C.I. Sze, H. Bi, B.K. Kleinschmidt-DeMasters, C.M. Filley, and L.J. Martin Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains J. Neurol. Sci. 175 2000 81 90
29. C.I. Sze, J.C. Troncoso, C. Kawas, P. Mouton, D.L. Price, and L.J. Martin Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease J. Neuropathol. Exp. Neurol. 56 1997 933 944
30. R.D. Terry The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis J. Neuropathol. Exp. Neurol. 55 1996 1023 1025
31. J.B. Watson, I. Szijan, and P.M. Coulter Jr. Localization of RC3 (neurogranin) in rat brain subcellular fractions Brain Res. Mol. Brain Res. 27 1994 323 328
32. Z. Xia, and D.R. Storm The role of calmodulin as a signal integrator for synaptic plasticity Nat. Rev. Neurosci. 6 2005 267 276